REXULTI® (Brexpiprazole) FDA Approved for Treating Agitation in Alzheimer's Disease Patients

REXULTI® (brexpiprazole) has been approved by the FDA for treating agitation associated with dementia due to Alzheimer's disease, making it the first and only pharmacological treatment for this indication in the US.

FDA Approves First-Ever Drug for Agitation Associated with

FDA Approves First Drug Meant to Ease Alzheimer's-Linked Agitation

FDA advisers back Lundbeck and Otsuka's Rexulti in Alzheimer's

JAMA Neurology Publishes Complete Results of Positive Phase 3

Bioxcel shares plunge on FDA warning letter despite promising data

REXULTI® (brexpiprazole) Agitation associated with dementia due

FDA Approves First Drug for Alzheimer's-Related Agitation Symptoms

Otsuka and Lundbeck Announce REXULTI for Alzheimer's Agitation

FDA Approves First Treatment for Alzheimer's Agitation